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A B S T R A C T
Oxysterol-binding protein (OSBP)-related proteins (ORPs) constitute a family of intracellular lipid-binding/
transport proteins (LTPs) in eukaryotes. They typically have a modular structure comprising a lipid-binding
domain and membrane targeting determinants, being thus suited for function at membrane contact sites. Among
the mammalian ORPs, ORP2/OSBPL2 is the only member that only exists as a ‘short’ variant lacking a mem-
brane-targeting pleckstrin homology domain.
ORP2 is expressed ubiquitously and has been assigned a multitude of functions. Its OSBP-related domain
binds cholesterol, oxysterols, and phosphoinositides, and its overexpression enhances cellular cholesterol efflux.
Consistently, the latest observations suggest a function of ORP2 in cholesterol transport to the plasma membrane
(PM) in exchange for phosphatidylinositol 4,5-bisphosphate (PI4,5P2), with significant impacts on the con-
centrations of PM cholesterol and PI4,5P2. On the other hand, ORP2 localizes at the surface of cytoplasmic lipid
droplets (LDs) and at endoplasmic-reticulum-LD contact sites, and its depletion modifies cellular triglyceride
(TG) metabolism. Study in an adrenocortical cell line further suggested a function of ORP2 in the synthesis of
steroid hormones. Our recent knock-out of ORP2 in human hepatoma cells revealed its function in hepatocellular
PI3K/Akt signaling, glucose and triglyceride metabolism, as well as in actin cytoskeletal regulation, cell adhe-
sion, migration and proliferation. ORP2 was shown to interact physically with F-actin regulators such as
DIAPH1, ARHGAP12, SEPT9 and MLC12, as well as with IQGAP1 and the Cdc37-Hsp90 chaperone complex
controlling the activity of Akt. Interestingly, mutations in OSBPL2 encoding ORP2 are associated with autosomal
dominant non-syndromic hearing loss, and the protein was found to localize in cochlear hair cell stereocilia.
The functions assigned to ORP2 suggest that this protein, in concert with other LTPs, controls the subcellular
distribution of cholesterol in various cell types and steroid hormone synthesis in adrenocortical cells. However, it
also impacts cellular TG and carbohydrate metabolism and F-actin-dependent functions, revealing a bewildering
spectrum of activities.
1. Introduction
ORP2 was initially discovered in 1999 in a screen for oxysterol-
binding protein (OSBP) related expressed sequence tags [1]. The full-
length human cDNA was reported in 2001 [2–4] and the mouse or-
thologue in 2002 [5]. The ORP2 mRNA was observed ubiquitously in
human [1] and mouse [5] tissues. ORP2 belongs, based on its amino
acid sequence and gene structure, to ORP subfamily II, together with
the closely related ORP1 [3]. ORPs share a characteristic β-barrel-
resembling ligand-binding domain designated OSBP-related domain
(ORD) in their carboxy-terminal region [3,6–8]. While all other mam-
malian OSBPL/Osbpl genes encode ORP proteins of the ‘long’ subtype,
carrying an amino-terminal extension that contains a pleckstrin
homology (PH) domain, ORP2 only exists as a ‘short’ subtype protein
lacking a pH domain (Fig. 1; [2,3,5]). Another membrane targeting
determinant present in most ORPs is called two phenylalanines in an
acidic tract (FFAT) which mediates binding of the protein to the in-
tegral type 2 membrane proteins of the endoplasmic reticulum (ER),
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VAMP-associated proteins A and B (VAPA,VAPB [9];). For two ORPs
(ORP5 and ORP8) this functional motif is replaced by an ER-targeting
trans-membrane segment [10,11].
The presence of the ER-targeting motifs and pH domains or a trans-
membrane segment confers ORPs the capacity to associate with two
distinct membrane organelles at membrane contact sites (MCSs), and
the current paradigm postulates that ORPs execute lipid transport and
signaling functions at such intimate, direct organelle contacts [12–14].
The lipid transport function of ORPs involves a ‘countercurrent’ me-
chanism, in which a substrate lipid (thus far evidence exists for cho-
lesterol or phosphatidylserine) is transferred in exchange for phospha-
tidylinositol-4-phosphate (PI4P [15–20];) or another
polyphosphoinositide such as PI4,5P2 [21]. A crucial part of the
transport cycle is the hydrolysis of the countertransported PI4P by the
ER phosphoinositide phosphohydrolase Sac1 [22]. ORP2 does carry
close to its amino-terminus a FFAT motif and thus binds to VAP proteins
at the ER [23]. However, it lacks the pH domain and associated
membrane targeting function. In this focused review we summarize the
current knowledge on the function of ORP2.
2. Tissue expression pattern and subcellular localization of ORP2
The early reports on the identification of ORP/OSBPL sequences
demonstrated that the ORP2 mRNA is detectable in all human and
mouse tissues [1–3,5,24]. In western analysis of mouse tissues also the
protein was observed in all tissues, with the strongest signal detected in
the brain [24]. Two protein variants, with the apparent molecular
masses of 51 and 56 kDa in SDS-PAGE were observed, with tissue-
specific differences in their abundance. The identity of these protein
variants has not been determined.
Cell fractionation by Laitinen et al. [24] suggested that a major
portion of the endogenous ORP2 in Chinese hamster ovary (CHO) cells
is cytosolic; however, part of the protein was found in the membrane
fraction. Early overexpression studies in CHO cells indicated localiza-
tion of ORP2 at the Golgi complex, consistent with a Golgi vesicle
transport defect observed in CHO cells overexpressing this protein
[4,24]. However, later work revealed prominent localization of ORP2
on the surface of cytoplasmic lipid droplets (LDs) in A4312, HeLa,
HepG2 and COS-7 cells, with no detectable Golgi targeting [25]. Of
interest, incubation of cells with the high affinity ligand of ORP2,
22(R)-hydroxycholesterol (OHC), resulted in a different, diffuse and cell
cortex/plasma membrane (PM) localization of the protein [25]. A site-
specific mutant deficient in oxysterol binding, ORP2 I249W [26],
showed enhanced association with LDs and could not be detached
therefrom with 22(R)OHC, suggesting that oxysterol binding controls
the conformation of ORP2 and this, in turn, plays a crucial role in its
targeting to LDs [25].
Several years later, Weber-Boyvat et al. [23] investigated in HuH7
hepatoma cells the subcellular localization of complexes of ORP2 with
its ER anchor, VAPA, by using the bimolecular fluorescence com-
plementation (BiFC) technique. They detected ORP2-VAPA complexes
at ER-LD contacts. Moreover, siRNA-mediated knock-down of ORP2
and VAPs enhanced the turn-over of cellular triglycerides. These ob-
servations suggested that a major function of ORP2 could involve the
ER-LD interfaces and the TG metabolic processes occurring therein.
However, the study of Kentala et al. [27] revealed that the loss of ORP2
did not reduce ER-LD contacts, but under basal culture conditions ra-
ther increased them. However, this work indicated that the dynamic
expansion of the ER-LD MCSs upon fatty acid loading may be disturbed
in the ORP2 KO cells. Similar to ORP2 expressed alone, ORP2-VAPA
BiFC complexes were upon 22(R)OHC treatment redistributed from LD-
associated ER structures to elongated membraneous-appearing ele-
ments and occasionally to the cell cortex/PM [28]. Cell cortex locali-
zation of ORP2 was also observed in human umbilical vein endothelial
cells (HUVECs) that seldom have large LDs. In these cells, the protein
was frequently found co-localizing with the actin regulator cortactin in
lamellipodia [27].
If cells have large LDs or are subjected to fatty acid loading to in-
crease LD size, ORP2 associates prominently with LDs (Fig. 2A). How-
ever, many cultured cell lines display under standard growth conditions
only very small or undetectable LDs. Under these conditions the cyto-
solic and other non-LD aspects of ORP2 localization, such as the cell
cortex/PM and lamellipodia (Fig. 2B), predominate. The recent study of
Koponen et al. [29] revealed a previously undiscovered localization of
the protein on late endosomes (LE) labeled with anti-Lamp1 or inter-
nalized fluorescent dextran (Fig. 2C).
To summarize, exogenously expressed ORP2 targets LDs or ER-LD
contacts, but in the absence of large LDs, it remains largely cytosolic or
and/or targets the cell cortex/PM and LEs. When co-expressed with
VAPA, ORP2 is seen attached to the ER and prominently at ER-LD
contacts. A major problem is that, with the antibodies we have gener-
ated or those available commercially it has been difficult to reliably
detect the endogenous cellular ORP2. Some efforts have, however, been
made. Our study [25] suggested that some endogenous ORP2 may be
detectable on the LDs of fatty acid loaded A431 cells. Thoenes et al.
[30] reported detection of endogenous ORP2 in the stereocilia of mouse
cochlear inner and outer hair cells. Moreover, Escajadillo et al. [31]
reported detection of endogenous ORP2 within the nucleus of adreno-
cortical H295R cells, consistent with their data suggesting its associa-
tion with the transcription factor liver X receptor (LXR). However, new
antibodies of better quality and independent confirmations in different
cell types, validated by ORP2 knock-down or knock-out, are required
before firm statements can be made on the subcellular localization of
endogenous ORP2.
3. Ligands of ORP2
A number of reports have addressed the lipid ligands of ORP2 by
employing charcoal-dextran, pull-down, lipid-protein overlay assays,
extraction of lipids from vesicles, or surface plasmon resonance (SPR)
(Table 1). Initially, the group of N. Ridgway investigated the lipidous
ligands of ORP2 by using a lipid-protein overlay assay. The results
suggested binding of ORP2 to the acidic lipids phosphatidic acid (PA),
phosphatidylinositol-3-phosphate (PI3P) and cardiolipin [4]. These re-
sults need to be interpreted with caution, since lipids spotted on ni-
trocellulose surface are presented to proteins in a rather non-physio-
logic manner. Our group next documented, by using a charcoal-dextran
assay, binding of the oxysterol 25OHC to ORP2 produced in E.coli as a
GST fusion, at a 3.9× 10−6 M Kd [26]. In a follow-up study [25] we
measured affinities of ORP2 for 22(R)OHC (1.4× 10-8 M) and 7-ke-
tocholesterol (7KC; 1.6×10-7 M) and presented evidence that the
protein also binds cholesterol, based on a pull-down assay in which
Fig. 1. Alignment of ORP2 protein with the closely related mem-
bers in subfamily II, ORP1L and ORP1S. ANK, ankyrin repeats; PH,
pleckstrin homology domain; FFAT, two phenylalanines in an
acidic tract; ORD, OSBP-related (ligand-binding) domain; OF,
OSBP fingerprint sequence (EQVSHHPP), a conserved sequence
motif with a crucial role in phosphoinositide binding. LE, late
endosome; VAP, VAMP-associated protein; ER, endoplasmic re-
ticulum; PIP, phosphoinositide.
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ORP2 extracted cholesterol from methyl-β-cyclodextrin. Our latest
work confirmed the cholesterol binding, by employing a pull-down
assay in which radiolabeled cholesterol was solubilized with the zwit-
terionic detergent CHAPS. However, the binding did not reach satura-
tion, so we were unable to determine a Kd for this interaction [29].
In addition to a PIP-binding pH domain, several ORPs have the
capacity to accommodate and extract PI4P and other PIPs by their ORD
domain [15–17,21]. In 2005 we showed that ORP2 is capable of pulling
down phosphatidylcholine (PC) vesicles with 2mol% (unlabeled)
multiply phosphorylated PIPs, the pull-down being most efficient with
PI3,4,5P3 [32]. This suggested an interaction of ORP2 with the head
groups of long-chain PIPs in vitro on vesicle surfaces, since extraction of
a PIP by the ORD would not result in pull-down of the vesicles labeled
with [14C]PC. In the latest study we assessed the binding of soluble
short-chain (di-C8) PIPs, PI4P, PI4,5P2, and PI3,4,5P3 to Strep-tagged
ORP2 immobilized on SPR chips. The signal obtained in this assay may
represent binding of the PIPs within the ORD pocket, but also interac-
tion of the PIPs with the surface of ORP2 could contribute to the signal.
ORP2 bound PI4,5P2 at 52 μM, PI3,4,5P3 at 76 μM, and PI4P at a
305 μM Kd [29]. However, the data need to be considered with some
caution, since the folding status of ORP2 fusion proteins produced in E.
coli has not been assessed in detail. Importantly, Wang et al. [33] re-
cently solved the high-resolution structure of the ORP2 ORD with
bound PI4,5P2 and reported that the protein binds this PIP as a tet-
ramer. They also demonstrated binding of the other six PIPs by em-
ploying an in vitro assay in which the ORD extracted the PIPs from
vesicles (Table 1). The above reports suggest that the ORP2 ORD may
show higher affinity for multiply phosphorylated PIPs than for PI4P.
Published data suggests that PI4,5P2 and possibly PI3,4,5P3 may be the
most important PIP ligands of ORP2 at the PM [29,32,33], and we
hypothesize that it could bind PI3,5P2 on LE/lysosomes, since ORP2
binds this late endocytic pathway membrane component quite effi-
ciently on vesicle surfaces in vitro [32].
4. Roles of ORP2 in cellular sterol and steroid hormone
metabolism
Overexpression of ORP2 in CHO or HeLa cells was initially found to
enhance the efflux of cellular radioisotope-labeled cholesterol to all
acceptors, including human serum, apoA-I, and small unilamellar
phosphatidylcholine vesicles [24,32], as well as the appearance of
metabolically labeled newly synthesized cholesterol at the cell surface
Fig. 2. Fluorescence microscopy images de-
picting the various subcellular localizations of
ORP2. A. Biomolecular fluorescence com-
plementation (BiFC) analysis of ORP2-VAPA
complexes in human umbilical vein endothelial
cells (HUVECs) transfected for 24 h by elec-
troporation (Nucleofector™, Lonza Bioscience).
Note the reticular ER pattern and intense
staining at ER domains encircling lipid droplets
(LDs) stained with BODIPY-C12 (Molecular
Probes/Thermo Scientific). B. Localization of
ORP2-GFP at the cell cortex, where it co-loca-
lizes with the lamellipodial marker cortactin
(stained with monoclonal antibody 4F11;
Upstate Biotechnology). C. Localization of
ORP2-GFP in late endosomes/lysosomes iden-
tified by using internalized Alexa Fluor™647-
dextran (Molecular Probes/Thermo Scientific).
V.M. Olkkonen, et al. Journal of Steroid Biochemistry and Molecular Biology 192 (2019) 105298
3
as detected by employing methyl-β-cyclodextrin [32](Fig. 3). These
observations suggested that abundant ORP2 in the cytosol of the stably
transfected cells facilitated the intracellular transport of cholesterol,
resulting in its rapid appearance at the cell surface measured by em-
ploying the efflux process or by a wash of cell surfaces with methyl-β-
cyclodextrin. The new hallmark study by the group of H. Yang [33]
demonstrated the capacity of ORP2 to transport cholesterol to the PM in
exchange for PI4,5P2: Its knock-out in HEK293 cells reduced the cho-
lesterol and increased the PI4,5P2 content of the PM, as well as con-
ferred the cells elevated resistance to the cholesterol-binding drug
amphotericin B. Further evidence for a direct sterol/PI4,5P2 exchange
or ‘countercurrent’ transfer activity of ORP2 was produced by in vitro
vesicle-to-vesicle lipid transfer assays. Jansen et al. [34] studied the
transport of cholesterol from the PM to lipid droplets in HeLa cells. In
an overexpression screen they identified ORP2 and another related
‘short’ ORP, ORP1S, as gene products whose overexpression speeded up
the movement of PM cholesterol to LDs. In more detailed analyses the
effect was localized to the initial PM to ER transport step (Fig. 3). To
determine whether also depletion of these ORPs would impact the
cholesterol transport process, siRNA-mediated knock-down was carried
out. Here, the double knock-down of ORP2 and ORP1S resulted in a
modest but significant reduction of cholesterol transfer to the ER and
LDs, supporting the involvement of the endogenous cellular proteins in
PM to ER cholesterol trafficking. Consistent with the observations of
Wang et al. [33], Koponen et al. [29] observed in a recent study carried
out with HeLa cells that knock-down of ORP2 or overexpression of a
mutant defective in PIP binding resulted in the accumulation of cho-
lesterol probes (a derivative of Clostridium perfringens toxin, D4H, or
filipin) in late endosomes, while overexpression of wild-type ORP2
shifted the D4H probe to the PM. These observations support the idea
that ORP2 plays an important role in intracellular cholesterol transport
to the PM – from endosomes and possibly other subcellular compart-
ments (Fig. 3). This would be consistent with the enhancement of
cholesterol efflux upon ORP2 overexpression [24,32], but somewhat at
odds with the data of Jansen et al. [34]. However, we find it possible
that ORP2 may be involved in several routes of cholesterol transport.
Kentala et al. [27,35] generated HuH7 hepatoma cells entirely de-
void of ORP2 by using the CRISPR-Cas9 technology. Analysis of the
lipidome of these cells revealed no change in free cholesterol (FC),
cholesterol ester (CE) or oxysterol (25OHC, 27OHC, 7αOHC, 7βOHC,
7KC) content [27]. Even challenge of the cells by sterol depletion by
employing lipoprotein-deficient serum plus statin treatment, or by LDL
loading, did not change the situation, suggesting that a chronic lack of
ORP2 did not distort cholesterol homeostatic regulation in the hepa-
toma cells. However, next generation RNA sequencing of the cells re-
vealed significant alterations in the mRNA expression of 11 key cho-
lesterol homeostatic genes, including HMGCR and SOAT1, indicating
that the depletion of ORP2 had disturbed the sterol homeostasis, but the
effects had been compensated for by adaptation via altered gene ex-
pression [27].
The results of Escajadillo et al. [31] in the adrenocortical H295R cell
line subjected to stable shRNA-mediated knock-down of ORP2 revealed
2.9-fold and 1.9-fold increases of cellular FC and 25OHC, respectively,
as well as significant reductions of 22OHC and 7KC. These changes
coincided with significant reductions in multiple steroid metabolites,
including progesterone, 11-deoxycortisol and cortisol, but increased
concentrations of androgens and estrogens. Moreover, knock-down of
ORP2 suppressed the expression of several proteins required for cortisol
biosynthesis and of the steroidogenic transcription factor SF1. The au-
thors presented evidence that ORP2 may interact with the nuclear re-
ceptor liver X receptor (LXR), and both proteins bind to the promoter of
CYP11B1 in response to cAMP signaling. CYP11B1 encodes steroid 11β-
hydroxylase, a key enzyme converting 11-deoxycortisol to cortisol in
the adrenal cortex. However, also a function of ORP2 in the transport of
cholesterol, a substrate for the synthesis of steroid hormones, could
obviously affect steroidogenesis. The observations are consistent with
Table 1
Lipidous ligands reported to bind to ORP2.
Ligand Assay method Kd Reference
Phosphatidic acid Lipid-protein overlay ND* [4]
Cardiolipin Lipid-protein overlay ND [4]
PI3P# Lipid-protein ND [4]
overlay
Extraction from ND [33]
vesicles
PI4P SPR§ 305×10−6 M [29]
Extraction from vesicles ND [33]
PI5P Extraction from vesicles ND [33]
PI3,4P2 Vesicle pull-down ND [32]
Extraction from vesicles ND [33]
PI3,5P2 Vesicle pull-down ND [32]
Extraction from vesicles ND [33]
PI4,5P2 Vesicle pull-down ND [32]
SPR 52×10−6 M [29]
X-ray crystallogr. Extraction
from vesicles
ND [33]
ND [33]
PI3,4,5P3 Vesicle pull-down ND [32]
SPR 76×10−6 M [29]
Extraction from vesicles ND [33]
22(R)OHC€ Charcoal-dextran 1.4× 10−8 M [25]
7KC& Charcoal-dextran 1.6× 10−7 M [25]
25OHC Charcoal-dextran x 10−6 M [26]
Photo-cross-linking ND [26]
Cholesterol Pull-down ND [25,29]
Dehydroergosterol Extraction from vesicles ND [33]
* Not determined.
# Phosphatidylinositol-3-phosphate.
§ Surface plasmon resonance.
€ Hydroxycholesterol.
& Ketocholesterol.
Fig. 3. A schematic image depicting the reported functions of ORP2 in cellular
cholesterol and steroid metabolism. The references from which each piece of
information originates are indicated in brackets. Published data suggest roles of
ORP2 in cholesterol transport from late endosomes (LE)/lysosomes and possibly
other compartments to the plasma membrane [29,33], in transcriptional reg-
ulation of sterol metabolism and steroidogenesis [31], in cholesterol efflux from
cells [24,32], and cholesterol transport from the plasma membrane to the ER
and lipid droplets (LD) [34]. ORP2 is detached from LDs by the high-affinity
ligand 22(R)-hydroxycholesterol [22(R)OHC] [25]. LXR, liver X receptor; SF1,
steroidogenic factor 1; ER, endoplasmic reticulum; CE, cholesterol ester;
CYP11B1, cytochrome P450 family 11 subfamily B member 1; ABCA1, ATP-
binding cassette transporter A1; HDL, high-density lipoprotein.
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an earlier finding by the same group identifying ORP2 as an interaction
partner of the formin family protein diaphanous homologue 1
(DIAPH1), a Rho GTPase effector which regulates cortisol production
by controlling the rate of mitochondrial movement [36]. Of note,
DIAPH1 regulates cytoskeletal dynamics by interacting with actin,
microtubules and other cytoskeletal-associated regulatory proteins
([37]; see section 7). The above observations suggest that ORP2 exe-
cutes in steroidogenic cells specific functions in the synthesis of steroid
hormones, transcriptional regulation apparently playing an important
role therein (Fig. 3).
5. Impacts of ORP2 manipulations on triglyceride metabolism
Discovery of ORP2’s affinity for LD surfaces [25] and a reduction of
TGs observed in CHO cells stably overexpressing ORP2 [38] suggested
that the protein may execute a function in cellular neutral lipid meta-
bolism. We therefore analyzed the impacts of ORP2 knock-down in
A431 cells on LD morphology and biochemically on the turn-over of
cellular TGs. Upon ORP2 knock-down, the consumption of LDs in re-
sponse to lipid starvation was slowed down in morphological analyses;
Consistently, biochemical analyses revealed that the break-down of
radioisotope-labeled TGs was slowed down in the knock-down cells
[25]. These observations suggested that ORP2, presumably at the LD
surface, may facilitate the consumption of stored TGs upon fatty acid
depletion. Weber-Boyvat et al. [23] discovered in HuH7 hepatoma cells
that knock-down of ORP2 together with its ER anchors VAPA and -B,
speeded up the consumption of radioisotope-labeled TGs upon lipid
depletion. Knock-down of ORP2 alone had in this case no significant
effect on the TGs. The results appeared contradictory to those of Hy-
nynen et al. [25], perhaps due to a different cell model employed, but
nevertheless supported a functional role of ORP2 as a regulator of TG
metabolism.
The complete knock-out of ORP2 in the HuH7 hepatoma cell model
[27] revealed as the only significant lipidome change, reduced TG
storage, and consistently, reduced synthesis of TGs in pulse labeling
experiments. RNA sequencing showed a reduced expression of the li-
pogenic transcription factor SREBP-1 and a large number of its estab-
lished target genes such as FASN and SCD, suggesting that the loss of
ORP2 may result in transcriptional down-regulation of the hepatocel-
lular lipogenesis. A possible underlying mechanism was proposed: We
found defective activity of the Ser/Thr kinase Akt, a key regulator of
cell metabolism and viability, in the ORP2 knock-out cells. Since Akt
has been documented to control the activity of SREBP-1 [39–41], de-
fective Akt signaling could provide a plausible explanation for the re-
duction of SREBP-1 dependent transcription and lipogenesis (Fig. 4). To
summarize, a number of evidences based on acute knock-down or
complete knock-out of ORP2 in different cell types support a functional
role of the protein as a regulator of cellular TG metabolism, in addition
to a function in cholesterol transport.
6. Function of ORP2 in the carbohydrate metabolism of hepatoma
cells
Having consistently observed impacts of ORP2 knock-down/knock-
out on TG metabolism, we wanted to investigate whether these impacts
actually extend wider in the cellular energy metabolism, including that
of carbohydrates. Analyses of the ORP2 knock-out HuH7 hepatoma
cells revealed significant defects in glucose uptake, glycogen synthesis
and glycolysis [27] (Fig. 4). Since glucose metabolism is robustly
regulated by insulin via the PI3K/Akt signaling pathway, we assessed
the activating Ser473 phosphorylation of Akt and the Ser9 phosphor-
ylation of Akt’s target glycogen synthase kinase 3β (GSK-3β), a central
regulator of glycogen synthesis [42]. We observed a substantial re-
duction of both phosphorylations, suggesting that the loss of ORP2
indeed results in defective Akt signaling (Fig. 4). The mechanisms
through which ORP2 affects the activity of Akt require further study.
However, we managed to find some clues of this: (i) ORP2 was found to
physically interact with IQGAP1 [35], a protein acting as a scaffold for
phosphoinositide kinases [43] in the cascade that eventually produces
PI3,4,5P3, a key messenger in the PI3K/Akt signaling pathway and (ii)
ORP2 was found to physically interact with Cdc37 and Hsp90 [27],
which form a chaperone complex required for Akt activity [44]. The
above results suggested that ORP2 not only regulates the cellular TG
metabolism, but has more global impacts on energy metabolism. This
function could be in part mediated by ORP2’s involvement in inter-
organelle lipid transport, potentially resulting in altered lipid domain
organization with secondary effects on signaling. However, we also
identified protein-protein interactions that most likely are of im-
portance. Of note, defective Akt signaling upon ORP2 depletion was not
only observed in the cancerous hepatoma cell line, but also in primary
human umbilical vein endothelial cells [27]. It will be extremely in-
teresting to study insulin signaling, lipid and carbohydrate metabolism
in vivo in Osbpl2 knock-out mice.
7. ORP2 in cell F-actin regulation, adhesion, migration and
proliferation
The RNA sequencing of ORP2 knock-out hepatoma cells by Kentala
et al. [35] revealed significant changes in the expression of genes in the
functional categories ‘Cellular movement’, ‘Cell–cell signalling and in-
teraction’, ‘Cellular development’,’ Cellular function and maintenance’,
‘Cellular growth and proliferation’, ‘Cell morphology’, and ‘Cell Death
and Survival’. A number of pathways in these categories involved the
actin cytoskeleton, cell migration, adhesion or proliferation. Moreover,
analysis of the ORP2 protein interactome in HuH7 cells uncovered
>100 putative new partners, pathway analysis of which revealed
‘RhoA signalling’ as the most significant ORP2-associated pathway.
Interactions of ORP2 with the actin regulatory components SEPT9,
MLC12, ARHGAP12 and IQGAP1 were validated by independent as-
says. Consistently, loss of ORP2 resulted in abnormal F-actin mor-
phology characterized by impaired capacity to form lamellipodia, a
migration defect and reduced rates of adhesion to substratum and
proliferation. The results point at a novel function of ORP2 as a reg-
ulator of the actin cytoskeleton, with impacts on hepatocellular mi-
gration, adhesion, and proliferation. However, one has to bear in mind
Fig. 4. A schematic model on the function of ORP2 in PI3K/Akt signaling and
cellular energy metabolism. The Akt signaling pathway is stimulated by growth
factors (such as insulin), which bind to plasma membrane (PM) growth factor
receptors (GFR) resulting in the activation of phosphoinositide-3-kinase (PI3K).
PI3K phosphorylates PIP2 to PIP3, which triggers the recruitment of phos-
phoinositide-dependent kinase 1 (PDK1) and Akt to the PM. ORP2 interacts
with IQGAP1 which scaffolds the phosphoinositide kinases at the PM. Akt in-
teracts at the PM with its effector complex Hsp90-Cdc37-ORP2 and is phos-
phorylated by PDK1. Active Akt regulates a number of downstream target
molecules (including glycogen synthase kinase 3, GSK3), resulting in increased
uptake of glucose, glycogen synthesis, glycolysis, and lipogenesis via sterol
regulatory element binding protein-1 (SREBP-1).
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that the above data is based on work with cancerous hepatic cells. It is
therefore important to carry out similar analyses in untransformed
primary hepatocytes in the future.
8. Mutations in OSBPL2 are associated with hereditary non-
syndromic hearing loss
Two studies reported in 2015 that human mutations in OSBPL2
associate with autosomal dominant non-syndromic hearing loss
(ADNSHL) [30,45]. The syndrome is genetically heterogeneous: 65 loci
and more than 30 causative genes have been designated. Thoenes et al.
[30] carried out genome-wide linkage analysis and whole exome se-
quencing, identifying a co-segregating heterozygous frameshift muta-
tion in OSBPL2, which truncates the encoded protein. Im-
munohistochemistry in mouse cochlea by using a commercial ORP2
antibody suggested the presence of ORP2 protein in the inner and outer
hair cell stereocilia, structures which strongly depend on F-actin [46].
Similar observations were reported in a large Chinese family by Xing
et al. [45], who also found a frameshift mutation in OSBPL2 co-segre-
gating with the ADNSHL phenotype. Moreover, they found another
missense mutation (c.583C>A transversion; p.Leu195Met) in the gene
in a sporadic case of the disease. Although the causality of these mu-
tations is not 100% certain, they make OSBPL2 an obvious candidate
gene for the disease, especially since also mutations in DIAPH1, an in-
teraction partner of ORP2 [36], are reported to cause hearing loss [47].
We find it likely that the association of OSBPL2 mutations with her-
editary hearing loss reflects a function of the protein in actin cytoske-
letal regulation (see Section 7). Whether the functional cross-talk of
ORP2 with the actin cytoskeleton involves sterol binding or transport
by the protein is largely unclear; However, the capacity of ORP2 re-
introduced into knock-out HuH7 cells to alter cell surface and F-actin
morphology and to replenish migration in a wound healing assay de-
pended on the ability of ORP2 to bind phosphoinositides [35], sug-
gesting that the F-actin associated function of ORP2 involves the
binding of PIPs by the protein.
9. Conclusions and future perspectives
Recent studies employing knock-down or knock-out of ORP2 in
different cell types have suggested a bewildering multitude of functions
for this lipid-binding protein: Cholesterol and PIP transport, steroid
hormone synthesis, TG metabolism, F-actin regulation, cell adhesion,
migration and proliferation. Although ORP2 lacks a membrane-tar-
geting PH domain, it can associate with membranes via its FFAT motif
and patches of charged amino acid residues [33]. The current data
suggests that it is capable of mediating inter-organelle lipid transport by
a’ countercurrent’ mechanism: the transport of cholesterol to the PM in
exchange for PI4,5P2 [33]. In this respect it thus resembles the ‘short’
yeast ORPs Osh4p, Osh6 and Osh7p [19,20]. In addition to lipid
transport and metabolism, ORP2 also executes functions in cell sig-
naling. This could obviously be secondary to changes in membrane lipid
compositions or lateral organization, but our recent findings suggest
that protein-protein interactions may play crucial roles here. The role of
ORP2 in PI3K/Akt signaling may involve interactions with IQGAP1,
Cdc37 and Hsp90, while its functions in F-actin regulation could in-
volve the observed interactions with DIAPH1, SEPT9, ARHGAP12 and
MLC12. Moreover, the capacity of ORP2 to bind and transport PIPs is
apparently important for its functions in F-actin regulation [35].
To gain a thorough understanding of the physiologic function of
ORP2, progress on three major goals is required: (i) The role of lipid
binding by ORP2 in terms of the functions of this protein in signaling
and F-actin regulation needs to be elucidated. (ii) ORP2/Osbpl2 knock-
out mice need to be carefully characterized in terms of their choles-
terol/lipid and carbohydrate metabolism, insulin signaling, hearing and
other F-actin-dependent physiologic processes. (iii) Since ORP2 is ex-
pressed ubiquitously in many cell types, its activities need to be
investigated in the functional contexts of distinct cell types both in
culture and in vivo by employing tissue/cell type-specific knock-out
animal models. Additionally, the localization of ORP2 at the ER, LDs
and late endocytic compartments raises questions of its possible func-
tions in ER stress responses and lipophagy. Elucidating in detail the
functions of ORP2 and other OSBP-related gene products will most
certainly open new avenues in the research of organelle lipid home-
ostasis and their coordination with signaling events that control func-
tions such as cell adhesion, motility and proliferation.
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